Patient-focused manufacturing models for personalised therapies

Unique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, CTMC, is challenging the status quo to achieve this and get them to patients.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine aiming to advance novel scientific breakthroughs into medicines developed rapidly and robustly to - ultimately - end cancer.

Taking learnings from the monoclonal antibody field to come up with a fit-for-purpose solution, Bock discusses his work in the joint venture between the MD Anderson Cancer Center and biopharmaceutical manufacturer Resilience – combining industrial manufacturing and development capabilities with the work of an academic medical centre.

CTMC’s is a “patient adjacent” manufacturing model – crucial when it comes to developing personalised therapies (especially when dealing with living cells), and Bock explains how patient-centric approaches streamline manufacturing processes, improve efficacy, and allow for that personalised treatment approach, particularly when the supply chain is local.

You can listen to episode 168a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!